Decreased HIV-associated T cell apoptosis by HIV protease inhibitors

AIDS Research and Human Retroviruses

Volumn 16, Issue 6, 2000, Pages 559-567

  Phenix, Barbara N ^a,b   Angel, Jonathan B ^a,b,c   Mandy, Francis ^d   Kravcik, Stephen ^c   Parato, Karl ^a,b   Chambers, Kelley A ^a,b   Gallicano, Keith ^b,c   Hawley Foss, Nanci ^b,c   Cassol, Sharon ^b,c   William Cameron, D ^a,b,c   Badley, Andrew D ^a,b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d HEALTH CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; T LYMPHOCYTE; VIREMIA; VIRUS LOAD;

APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DIDANOSINE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; JURKAT CELLS; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR; T-LYMPHOCYTES; VIRAL LOAD; ZIDOVUDINE;

EID: 0034630359     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200308972     Document Type: Article

References (39)

1. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998;351:543-549.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
3. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
4. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-1539.
5. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, and Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
6. Collier AC, Coombs RW, Schoenfeld DA, et al: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-1017.
7. Kaufmann D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study: CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998;351:723-724. [Research Letters]
8. Levitz SM: Improvement in CD4+ cell counts despite persistently detectable HIV load. N Engl J Med 1998;338:1074-1075.
9. Piketty C, Castiel P, Belec L, et al.: Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998;12:745-750.
10. Carr A, Emery S, Kelleher A, Law M, and Cooper DA: CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr 1996;13:320-326.
11. Krammer PH, Dhein J, Walczak H, et al.: The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 1994;142: 175-191.
12. Dhein J, Walczak H, Baumler C, Debatin K-M, and Krammer PH: Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature (London) 1995;373:438-441.
13. Irmler M, Thome M, Hahne M, et al.: Inhibition of death receptor signals by cellular FLIP. Nature (London) 1997;388:190-195.
14. Alderson MR, Tough TW, Davis-Smith T, et al.: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-77.
15. Gougeon M-L, Lecoeur H, Dulioust A, et al.: Programmed cell death in peripheral lymphocytes from HIV-infected persons. J Immunol 1996;156:3509-3520.
16. Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, et al.: Interleukin-1β converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J Exp Med 1997; 186:1365-1372.
17. Gandhi RT, Chen BK, Straus SE, Dale JK, Lenardo MJ, and Baltimore D: HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism. J Exp Med 1998;187:1113-1122.
18. Noraz N, Gozlan J, Corbeil J, Brunner T, and Spector SA: HIV-induced apoptosis of activated primary CD4+ T lymphocytes is not mediated by Fas-Fas ligand. AIDS 1997;11:1671-1680.
19. Badley AD, Dockrell D, Simpson M, et al.: Macrophage-dependent apoptosis of CD4+ lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med 1997;185:55-64.
20. Badley AD, Dockrell DH, Ziesmer S, et al.: In vivo analysis of Fas/Fas L interactions in HIV-infected patients. J Clin Invest 1998; 102:79-87.
21. Vermes I, Haanen C, Steffens-Nakken H, and Reutelingsperger C: A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 1995;184:39-51.
22. Badley AD, Parato K, Cameron DW, Kravcik S, Phenix BN, Ashby D, Kumar A, Lynch DH, Tschopp J, and Angel JB. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ 1999;6:420-432.
23. Patki AH, Georges DL, and Lederman MM: CD4+ T-cell counts, spontaneous apoptosis, and Fas expression in peripheral blood mononuclear cells obtained from human immunodeficiency virus type 1-infected subjects. Clin Diagn Lab Immunol 1997;4:736-741.
24. Giorgi JV, Liu LE, Hultin WG, Cumberland K, Hennessey K, and Detels R: Elevated level of CD38+ CD8+ cells in HIV infection add to the prognostic value of low CD4+ T cell level: Results of 6 years follow-up. J Acquir Immune Defic Syndr 1993;6:904-908.
25. Giorgi JV and Detels R: T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS Cohort Study. Clin Immunol Immunopathol 1989;52:10-14.
26. Angel JB, Kumar A, Parato K, et al.: Improvements in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998; 177:898-904.
27. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St. Clair M, Kotzin BL, Fox L, Heath Chiozzi M, Leonard JM, Rousseau F, Wade M, Roe J, Martinez A, and Kessler H: Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-79.
28. Andre P, Groettrup M, Klenerman P, de Guilit R, Booth BL Jr, Cerundolo V, Bonneville M, Jotereault F, Zinkernagel RM, and Lotteau V: An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998;95:13120-13124.
29. Miller DK: The role of the caspase family of cysteine proteases in apoptosis. Semin Immunol 1997;9:35-49.
30. Barker E, Kahn J, Fujimura S, and Levy JA: Protease inhibitors do not increase the CD4+ cell count in HIV-uninfected individuals. AIDS 1998;12(9):1117-1118.
31. Gallicano K, Sahai J, Ormsby E, Cameron DW, Pakuts A, and McGilveray I: Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients. Br J Clin Pharmacol 1993;36:128-131.
32. Flexner C: HIV-protease inhibitors. N Engl J Med 1998;338: 1281-1292.
33. Konvalinka J, Litterst MA, and Welker R: An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity. J Virol 1995;69:7180-7186.
34. Komai T, Ishikawa Y, Yagi R, Suzuki-Sunagawa H, Nishigaki T, and Handa H: Development of HIV-1 protease expression methods using the T7 phage promoter system. Appl Microbiol Biotechnol 1997;47:241-245.
35. Tomasselli AG, Hui JO, Adams L, et al.: Actin, tropinin C, Alzheimer amyloid precursor protein and pro-interleukin 1β as substrates of the protease from human immunodeficiency virus. J Biol Chem 1991;266:14548-14553.
36. Strack PR, West Frey M, Rizzo CJ, et al.: Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2. Proc Natl Acad Sci USA 1996;93:9571-9576.
37. Flamand L, Crowley RW, Lusso P, et al.: Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: Implications for HIV pathogenesis. Proc Natl Acad Sci USA 1998;95:3111-3116.
38. Kitanaka C and Kuchino Y. Caspase independent programmed cell death. Cell Death Differ 1999;6:508-515.
39. Pakker NG, Kroon Ed, Roos MT, et al.: Immune restoration does not invariably occur following long term HIV-1 suppression during antiretroviral therapy: INCAS Study Group. AIDS 1999;13: 203-212.